Table 1.

Patient and disease characteristics

Variables	Haplo-HSCT	≤5/8 HLA-matched UCB	6-8/8 HLA-matched UCB	P value comparing haplo- to UCB
				≤5/8	6-8/8
Number of subjects	375	188	145
Age, y				<.001	<.001
≤16	67 (18%)	70 (37%)	84 (58%)
17 to 29	132 (35%)	61 (32%)	26 (18%)
30 to 39	75 (20%)	34 (18%)	21 (15%)
40 to 49	101 (27%)	23 (12%)	14 (10%)
Sex				.13	.99
Male	202 (54%)	114 (61%)	78 (54%)
Female	173 (46%)	74 (39%)	67 (46%)
Race				.84	.06
Caucasian	235 (63%)	113 (60%)	100 (69%)
Non-Caucasian	109 (29%)	58 (31%)	28 (19%)
Not reported	31 (8%)	17 (9%)	17 (12%)
Performance score				<.0001	.31
90 to 100	235 (63%)	150 (80%)	101 (70%)
≤80	132 (35%)	37 (20%)	42 (29%)
Not reported	8 (2%)	1 (<1%)	2 (1%)
Comorbidity index				.20	<.0001
≤2	237 (63%)	129 (69%)	117 (81%)
≥3	138 (37%)	59 (31%)	28 (19%)
Recipient CMV serostatus				.74	.65
Negative	119 (32%)	57 (30%)	52 (36%)
Positive	254 (68%)	129 (69%)	92 (63%)
Not reported	2 (<1%)	2 (1%)	1 (<1%)
Disease				.003	.002
AML	193 (52%)	72 (38%)	53 (37%)
ALL	182 (49%)	116 (62%)	92 (63%)
Disease status				.02	.002
1st CR	233 (62%)	98 (52%)	68 (47%)
2nd CR	142 (38%)	90 (48%)	77 (53%)
Disease risk index				.17	.003
Low/intermediate	280 (75%)	130 (70%)	89 (62%)
High/very high	95 (25%)	57 (30%)	56 (39%)
Cytogenetic risk				.002	.06
Favorable	79 (21%)	61 (32%)	44 (30%)
Intermediate	116 (31%)	55 (29%)	48 (33%)
Poor	148 (40%)	68 (36%)	46 (32%)
Not reported	32 (9%)	4 (2%)	7 (5%)
Transplant period				<.0001	<.0001
2012-2014	64 (19%)	105 (58%)	67 (48%)
2015-2017	272 (81%)	77 (42%)	73 (52%)